BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Decker T, Overkamp F, Rösel S, Nusch A, Göhler T, Indorf M, Sahlmann J, Trarbach T. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). BMC Cancer 2017;17:499. [PMID: 28743247 DOI: 10.1186/s12885-017-3492-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dong L, Zhu LN, Xie BJ, Li JB, Ding T, Jiang YF, Zhu ZN. Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis. Pharmacotherapy 2019;39:1126-36. [PMID: 31692005 DOI: 10.1002/phar.2344] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Gomez-roca C, Italiano A, Le Tourneau C, Cassier P, Toulmonde M, D’angelo S, Campone M, Weber K, Loirat D, Cannarile M, Jegg A, Ries C, Christen R, Meneses-lorente G, Jacob W, Klaman I, Ooi C, Watson C, Wonde K, Reis B, Michielin F, Rüttinger D, Delord J, Blay J. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Annals of Oncology 2019;30:1381-92. [DOI: 10.1093/annonc/mdz163] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
3 Badodekar N, Sharma A, Patil V, Telang G, Sharma R, Patil S, Vyas N, Somasundaram I. Angiogenesis induction in breast cancer: A paracrine paradigm. Cell Biochem Funct 2021;39:860-73. [PMID: 34505714 DOI: 10.1002/cbf.3663] [Reference Citation Analysis]
4 Yao S, Janku F, Koenig K, Tsimberidou AM, Piha-Paul SA, Shi N, Stewart J, Johnston A, Bomalaski J, Meric-Bernstam F, Fu S. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Med 2021. [PMID: 34841717 DOI: 10.1002/cam4.4446] [Reference Citation Analysis]
5 Ayoub NM, Jaradat SK, Al-shami KM, Alkhalifa AE. Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Front Pharmacol 2022;13:838133. [DOI: 10.3389/fphar.2022.838133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schröder H, Jaehnig P, Potthoff K, Lerchenmüller C. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer. Breast Cancer Res Treat 2019;176:637-47. [PMID: 31115844 DOI: 10.1007/s10549-019-05280-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Saha P, Talukdar AD, Nath R, Sarker SD, Nahar L, Sahu J, Choudhury MD. Role of Natural Phenolics in Hepatoprotection: A Mechanistic Review and Analysis of Regulatory Network of Associated Genes. Front Pharmacol 2019;10:509. [PMID: 31178720 DOI: 10.3389/fphar.2019.00509] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
8 Nair PC, Gillani TB, Rawling T, Murray M. Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact 2021;338:109401. [PMID: 33556367 DOI: 10.1016/j.cbi.2021.109401] [Reference Citation Analysis]
9 Saghatelyan T, Tananyan A, Janoyan N, Tadevosyan A, Petrosyan H, Hovhannisyan A, Hayrapetyan L, Arustamyan M, Arnhold J, Rotmann AR, Hovhannisyan A, Panossian A. Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine 2020;70:153218. [PMID: 32335356 DOI: 10.1016/j.phymed.2020.153218] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
10 Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer 2019;120:475-80. [PMID: 30745582 DOI: 10.1038/s41416-019-0391-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
11 Zhang M, Liu J, Liu G, Xing Z, Jia Z, Li J, Wang W, Wang J, Qin L, Wang X, Wang X. Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies. Cancer Lett 2021;520:422-33. [PMID: 34389434 DOI: 10.1016/j.canlet.2021.08.005] [Reference Citation Analysis]